Preliminary results show that onvansertib combined with FOLFIRI/bevacizumab has a manageable safety profile and good efficacy in the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (Ahn et al., 2024; Ahn et al., 2025). Here, KRAS is linked to metastatic colorectal cancer.